Shares of Precision BioSciences (NASDAQ:DTIL) rose 8.2% in pre-market trading after the company reported Q1 results.
Earnings per share rose 73.87% year over year to ($0.52), which were in line with the estimate of ($0.52).
Revenue of $6,998,000 rose by 28.12% from the same period last year, which beat the estimate of $4,260,000.
Earnings guidance hasn't been issued by the company for now.
Precision BioSciences hasn't issued any revenue guidance for the time being.
Company's 52-week high was at $23.67
Company's 52-week low was at $4.60
Price action over last quarter: Up 20.18%
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The company's segments include Therapeutics and Food.